Details of the Drug Combination

General Information of Drug Combination (ID: DCLRTBY)

Drug Combination Name

Picoplatin Hepzato

Indication

Disease Entry	Status	REF
Anaplastic large cell lymphoma	Investigative	[1]

Component Drugs

Picoplatin DM0PIY6

Hepzato DM2AZPP

Small molecular drug

N.A.

High-throughput Screening Result

Testing Cell Line: SR

Zero Interaction Potency (ZIP) Score: 4.05

Bliss Independence Score: 6.6

Loewe Additivity Score: 4.04

LHighest Single Agent (HSA) Score: 6.37

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Lung adenocarcinoma	DCNJ472	HOP-62	Investigative	[4]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
4	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.